Biogen and Mitsubishi Tanabe Pharma Conclude a License Agreement on MT-1303, a Therapeutic Agent for Autoimmune Diseases

Osaka, Japan, September 09, 2015 - Mitsubishi Tanabe Pharma Corporation (President & Representative Director, CEO: Masayuki Mitsuka, hereinafter, the Company) and Biogen (Headquarters: Massachusetts, U.S., CEO: George A. Scangos, hereinafter, Biogen) have concluded a License Agreement on MT-1303, a therapeutic agent for autoimmune diseases, discovered and developed by the Company.

MT-1303 developed by the Company, is a sphingosine-1-phosphate (S1P) receptor functional antagonist and, by inhibiting the receptor function of sphingosine-1-phosphate (S1P) receptor on the lymphocyte, keeps lymphocytes sequestered in the lymph nodes to prevent them from contributing to autoimmune reactions. Due to this mechanism, this compound may be potentially effective for various autoimmune diseases. The Company is currently conducting clinical trials for MT-1303 for multiple sclerosis, psoriasis, Crohn's disease and systemic lupus erythematosus in Europe and in Japan, and has obtained results suggesting a profile possibly safer than that of the existing S1P receptor functional antagonists. Considering these results, the Company decided to seek an alliance to accelerate development of this drug both in Japan and overseas, to launch the drug as soon as possible and to maximize its product value, and has concluded an agreement with Biogen, a company with an experience in this field.

In accordance with this agreement, the Company grants to Biogen the exclusive right to develop and market this drug globally except in Japan and in Asia. The Company has a right to participate in Biogen's global clinical trials as well as a co-promotion right in the United States in non-multiple sclerosis indications. Also, the Company receives an upfront payment of $60 million from Biogen. Moreover, the Company may receive up to $484 million in additional milestone payments according to territories and indications. The Company will receive royalties according to the sales volume after Biogen's marketing the product.
Please note that this agreement is subject to customary closing conditions, including the expiration of the applicable waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 in the United States, and is expected to close by the end of the calendar year 2015. Impact on the Company's results is under investigation and will be notified later.
Mitsubishi Tanabe Pharma Corporation has identified autoimmune diseases as one of its strategic areas and will aggressively work to develop new drugs that address unmet medical needs.

Reference

About Mitsubishi Tanabe Pharma Corporation
Mitsubishi Tanabe Pharma Corporation is a research-driven pharmaceutical company based in Osaka, Japan. MTPC is taking on the challenge of drug discovery in the fields of autoimmune disorders, central nervous system diseases, diabetes and kidney diseases, and vaccines. To those ends, MTPC is strengthening its R&D pipeline. MTPC contributes to the healthier lives of people around the world through the creation of pharmaceuticals. www.mt-pharma.co.jp/e.

About Biogen
Through cutting-edge science and medicine, Biogen discovers, develops and delivers to patients worldwide innovative therapies for the treatment of neurodegenerative diseases, hematologic conditions and autoimmune disorders. Founded in 1978, Biogen is one of the world’s oldest independent biotechnology companies and patients worldwide benefit from its leading multiple sclerosis and innovative hemophilia therapies. For product labeling, press releases and additional information about the company, please visit www.biogen.com.

Biogen Safe Harbor
This press release contains forward-looking statements, including statements about the potential benefits and developments that may be achieved through the license agreement with Mitsubishi Tanabe Pharma Corporation and the expected timing of the closing of the transactions. These statements may be identified by words such as “believe,” “expect,” “may,” “plan,” “potential,” “will” and similar expressions, and are based on Biogen’s current beliefs and expectations. These statements involve risks and uncertainties that could cause actual results to differ materially from those reflected in such statements. Risks and uncertainties that may cause actual results to differ materially include, among others: uncertainty inherent in the regulatory review process and satisfaction of other closing conditions relating to the transactions; uncertainty regarding the ability to achieve the expected benefits from the proposed license agreement, including as a result of risks and uncertainties associated with drug development and commercialization, reliance on third parties over which Biogen may not always have full control; and other risks and uncertainties that are described in the Risk Factors section of Biogen’s most recent annual or quarterly report filed with the Securities and Exchange Commission. Any forward-looking statements speak only as of the date of this press release and Biogen assumes no obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise.